Skip to main content
IMUX
NASDAQ Life Sciences

CEO Daniel Vitt to Receive $670K Retention Bonus Amidst Search for New CEO

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.17
Mkt Cap
$152.644M
52W Low
$0.506
52W High
$1.51
52W Position info
131% above low
Off High info
23% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

IMUX has more than doubled off its 52-week low of $0.506.

Summary

Immunic, Inc. is paying CEO Daniel Vitt a $670,000 retention bonus as it searches for a new CEO, with Vitt expected to transition to a scientific strategy role.


Key Events · Executive and Board Changes · IMUX

  • CEO Retention Bonus

    CEO Daniel Vitt will receive a $670,000 retention bonus, subject to his continued employment through the 91st day after a new CEO is hired.

  • Planned CEO Transition

    The company has begun a search for a new Chief Executive Officer. Daniel Vitt is expected to transition to a C-Suite role focused on scientific strategy and portfolio advancement.

  • Strategic Leadership Realignment

    This move aims to bring in new commercial expertise while retaining Mr. Vitt's scientific leadership, indicating a strategic shift in the company's executive structure.


Analysis · IMUX · Life Sciences

Immunic, Inc. is initiating a search for a new Chief Executive Officer, with current CEO Daniel Vitt expected to transition into a C-Suite role focused on scientific strategy. This retention bonus aims to ensure Mr. Vitt's continued employment and facilitate a smooth leadership transition. The move signals a strategic shift in leadership focus, bringing in new commercial expertise while retaining valuable scientific leadership.

How filings like this one have moved

In the 30 days to Sep 11, 2026, 30.2% of the 1961 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IMUX was trading at $1.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $152.6M. The 52-week trading range was $0.51 to $1.51. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IMUX - Latest Insights

IMUX
Sep 09, 2026, 9:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.26
Real-time Price: $11.31 info
Change: -$1.95 (-15%) info
Market Cap: $154.319M info
IMUX
Aug 11, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.10
Real-time Price: $11.31 info
Change: -$2.79 (-20%) info
Market Cap: $154.319M info
IMUX
Aug 11, 2026, 6:59 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.10
Real-time Price: $11.31 info
Change: -$2.79 (-20%) info
Market Cap: $154.319M info
IMUX
Jul 14, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.60
Real-time Price: $11.31 info
Change: -$3.29 (-23%) info
Market Cap: $154.319M info
IMUX
Jun 29, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $15.41
Real-time Price: $11.31 info
Change: -$4.10 (-27%) info
Market Cap: $154.319M info